Wellington Management Group LLP Lowers Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Wellington Management Group LLP reduced its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 4.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 496,227 shares of the biotechnology company’s stock after selling 24,967 shares during the period. Wellington Management Group LLP owned approximately 0.33% of Heron Therapeutics worth $987,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Clearline Capital LP boosted its stake in Heron Therapeutics by 48.9% in the 3rd quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company’s stock worth $4,431,000 after purchasing an additional 731,246 shares in the last quarter. Verition Fund Management LLC raised its holdings in Heron Therapeutics by 340.0% in the third quarter. Verition Fund Management LLC now owns 108,115 shares of the biotechnology company’s stock worth $215,000 after buying an additional 83,542 shares during the last quarter. Capstone Investment Advisors LLC bought a new position in shares of Heron Therapeutics in the third quarter worth approximately $45,000. Glenmede Trust Co. NA grew its holdings in shares of Heron Therapeutics by 49.6% during the third quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 10,578 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in shares of Heron Therapeutics by 50.4% during the third quarter. BNP Paribas Financial Markets now owns 275,946 shares of the biotechnology company’s stock valued at $549,000 after acquiring an additional 92,425 shares in the last quarter. 80.01% of the stock is currently owned by institutional investors.

Heron Therapeutics Stock Down 2.5 %

HRTX opened at $1.53 on Friday. The stock has a market capitalization of $232.71 million, a price-to-earnings ratio of -8.50 and a beta of 1.67. The firm has a 50 day moving average price of $1.56 and a 200-day moving average price of $2.23. Heron Therapeutics, Inc. has a twelve month low of $1.04 and a twelve month high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03). The company had revenue of $32.81 million for the quarter, compared to analysts’ expectations of $36.40 million. During the same quarter in the prior year, the firm posted ($0.17) earnings per share. As a group, analysts expect that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

Analyst Ratings Changes

HRTX has been the topic of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research report on Wednesday, December 4th. StockNews.com cut Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.